Gilead begins tenofovir alafenamide Phase 3 HIV study
Each of the double-blind Phase 3 trials will randomize 840 HIV-1 infected patients containing a viral load of 1,000 copies/mL or more with a once-daily tablet containing TAF
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.